Generalized – Talk Bio

Resilience Through Reinvention: How Pharma is Navigating Uncertainty During Turbulent Times

3 weeks ago talkbio0Tagged adaptation, Apis (invertebrate), Clinical Trials, drug price, Generalized, Investments, manufacturing uncertainty, Market, Pharma, Policy, regulatory environment, Reinvention, resilience, strategic reserves, supply chain

pharma; resilience; reinvention; supply chain; manufacturing uncertainty; regulatory environment; global market adaptation; funding; investment; clinical trials; drug pricing policy; APIs; strategic reserves

Fierce Biotech Layoff Tracker 2025: 10x Genomics cuts 8% of global workforce; NGM sheds 75% of staff

4 months ago talkbio0Tagged 2025, 75%, 8, Fierce, Generalized, Genomics, NGM, Staff

NGM, Genomics, Fierce, 8, Generalized, Staff, 75%, 2025

Global Pharmaceutical Stocks Plummet Amid Trump’s Imminent Tariff Threats

5 months ago talkbio0Tagged chain disruption, drug manufacturing, Generalized, pharma policy, pharmaceutical tariffs, pharmaceutical trade war, Trump import tariffs, United States

Pharmaceutical tariffs, global pharma stocks, Trump import tariffs, drug manufacturing, supply chain disruption, pharmaceutical trade war, U.S. pharma policy

Trump Withdraws US from World Health Organization, Sparking Concerns Over Global Health Security

8 months ago talkbio0Tagged Communicable Diseases, COVID19 (disease), Generalized, health security, Pandemics, public health medicine (field), Transplant Registry Unified Management Program, WHO, Withdraw (activity), World Health Organization

Trump, World Health Organization, WHO, withdrawal, global health security, infectious diseases, pandemics, COVID-19, public health experts.

Pfizer Withdraws Sickle Cell Disease Treatment Oxbryta Globally Due to Safety Concerns

12 months ago talkbio0Tagged Anemia, Sickle Cell, Clinical Trials, concerns, Event, Fatal, Generalized, Market, Oxbryta, Pfizer, Safety, vaso-occlusive crises, Withdraw (activity)

Pfizer, Oxbryta, sickle cell disease, global market withdrawal, safety concerns, clinical trials, vaso-occlusive crises, fatal events

Bluebird Bio’s Fertility Support Program for Gene Therapies Rejected by HHS Inspector General

1 year ago talkbio0Tagged Anti-Kickback Rules, CHARGE Syndrome, Family Turdidae (organism), Fertility, gene therapy, Generalized, Inspector, Skysona, Support, device

Bluebird Bio, Gene Therapy, Fertility Support, HHS Inspector General, Zynteglo, Skysona, Anti-Kickback Rules

Palleos Healthcare and OCT Global Unite to Form Comprehensive European Contract Research Organization ###

1 year ago talkbio0Tagged Clinical Research, Contract Research Organization, CRO, European (ethnic group), Generalized, Merger, Palleos Healthcare

Palleos Healthcare, OCT Global, European CRO, Merger, Clinical Research, Contract Research Organization

AstraZeneca Invests $1.5 Billion in Singapore for State-of-the-art Antibody-Drug Conjugate Manufacturing Facility

1 year ago talkbio0Tagged Antibody-Drug Conjugates, AstraZeneca, Biotechnology, Cancer Therapeutic Procedure, end-to-end, expansion, Facility (object), Generalized, innovation, Investments, Singapore

AstraZeneca, Singapore, investment, antibody-drug conjugate (ADC), manufacturing facility, end-to-end production, biotechnology, pharmaceuticals, cancer treatment, innovation, global expansion.

Ono Pharmaceutical Strengthens Oncology Portfolio with Acquisition of Deciphera Pharmaceuticals for $2.4 Billion

1 year ago talkbio0Tagged Acquisition (action), cancer treatments, Clinical Development, Collaboration, Deciphera, Dosage Forms, expansion, Generalized, Market, Oncology Pipeline, strategic

Ono Pharmaceutical, Deciphera Pharmaceuticals, oncology pipeline, acquisition, $2.4 billion, cancer treatments, kinase inhibitors, strategic expansion, global market, clinical development, collaboration.

Bristol Myers and Cellares Collaborate on Global CAR-T Manufacturing Deal

1 year ago talkbio0Tagged Biopharma, CAR-T, Cellares, diversification, Generalized, Manufacture, Myers, Partner in relationship

Bristol Myers, Cellares, CAR-T, biopharma, manufacturing partners, diversification, global deal